Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.45 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.45 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 3/20 | 0.42 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.42 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | CYP24A1 | Q07973 | 1/20 | 0.42 |
| ▸ | NPC1 | O15118 | 4/20 | 0.42 |
| ▸ | RAB9A | P51151 | 3/20 | 0.42 |
| ▸ | MLYCD | O95822 | 1/20 | 0.42 |
| ▸ | OGG1 | O15527 | 1/20 | 0.41 |
| ▸ | HSP90AA1 | P07900 | 2/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22858693 | 1.00 | ALDH1A1 (0.48) | ALDH1A1KMT2AOPRM1OPRD1KDM4E | |
| SCHEMBL28507569 | 1.00 | ALDH1A1 (0.48) | ALDH1A1KMT2AOPRM1OPRD1KDM4E | |
| SCHEMBL22858947 | 0.86 | TRPV1 (0.40) | ALDH1A1KDM4EHPGDNPSR1SMN1; SMN2 | |
| SCHEMBL22859168 | 0.86 | TRPV1 (0.40) | ALDH1A1KDM4EHPGDNPSR1SMN1; SMN2 | |
| SCHEMBL28713773 | 0.86 | TRPV1 (0.40) | ALDH1A1KDM4EHPGDNPSR1SMN1; SMN2 | |
| SCHEMBL28502010 | 0.76 | NPC1 (0.44) | ALDH1A1KMT2AOPRM1OPRD1HPGD | |
| SCHEMBL22858979 | 0.75 | POLB (0.37) | ALDH1A1KMT2AOPRM1OPRD1KDM4E | |
| SCHEMBL28502196 | 0.75 | POLB (0.37) | ALDH1A1KMT2AOPRM1OPRD1KDM4E | |
| SCHEMBL22859165 | 0.75 | POLB (0.37) | ALDH1A1KMT2AOPRM1OPRD1KDM4E | |
| SCHEMBL889069 | 0.75 | MLYCD (0.63) | ALDH1A1KMT2AOPRM1OPRD1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12459958-B2 | Tricyclic compounds as HPK1 inhibitor and the use thereof | BEONE MEDICINES I GMBH (CH) | 2025-11-04 | — | — | US | disclosed |
| US-12454534-B2 | Pyrrolo[2,3-b]pyrazines as HPK1 inhibitor and the use thereof | BEONE MEDICINES I GMBH (CH) | 2025-10-28 | — | — | US | disclosed |
| CN-115073474-B | Pyrrolo [2,3-b ] pyrazines as HPK1 inhibitors and uses thereof | 百济神州有限公司 | 2024-10-18 | — | — | CN | disclosed |
| CN-114127067-B | Tricyclic compounds as HPK1 inhibitors and uses thereof | 百济神州有限公司 | 2024-08-23 | — | — | CN | disclosed |
| EP-4377318-A1 | PYRROLO [2, 3-B] PYRAZINE-BASED BIFUNCTIONAL COMPOUNDS AS HPK1 DEGRADERS AND THE USE THEREOF | BeiGene, Ltd. (KY) | 2024-06-05 | — | — | EP | disclosed |
| CN-118043324-A | Pyrrolo [2,3-b ] pyrazine-based bifunctional compounds as HPK1 degradants and uses thereof | 百济神州有限公司 | 2024-05-14 | — | — | CN | disclosed |
| CN-112239473-B | Process for preparing tricyclic compounds as HPK1 inhibitors | 百济神州(北京)生物科技有限公司 | 2023-12-08 | — | — | CN | disclosed |
| WO-2023006063-A1 | PYRROLO [2, 3-b] PYRAZINE-BASED BIFUNCTIONAL COMPOUNDS AS HPK1 DEGRADERS AND THE USE THEREOF | BEIGENE, LTD. (KY) | 2023-02-02 | — | — | WO | disclosed |
| CN-115073474-A | Pyrrolo [2,3-b ] pyrazines as HPK1 inhibitors and uses thereof | 百济神州有限公司 | 2022-09-20 | — | — | CN | disclosed |
| CN-115028639-A | Pyrrolo [2,3-b ] pyrazines as HPK1 inhibitors and uses thereof | 百济神州有限公司 | 2022-09-09 | — | — | CN | disclosed |
| US-20220267354-A1 | TRICYCLIC COMPOUNDS AS HPK1 INHIBITOR AND THE USE THEREOF | BEONE MEDICINES I GMBH (CH) | 2022-08-25 | — | — | US | disclosed |
| US-20220267333-A1 | PYRROLO[2,3-b]PYRAZINES AS HPK1 INHIBITOR AND THE USE THEREOF | BEONE MEDICINES I GMBH (CH) | 2022-08-25 | — | — | US | disclosed |
| EP-3994136-A1 | PYRROLO [2, 3-B] PYRAZINES AS HPK1 INHIBITOR AND THE USE THEREOF | BeiGene, Ltd. (KY) | 2022-05-11 | — | — | EP | disclosed |
| CN-114127067-A | Tricyclic compounds as HPK1 inhibitors and uses thereof | 百济神州有限公司 | 2022-03-01 | — | — | CN | disclosed |
| CN-114096536-A | Pyrrolo [2,3-b ] pyrazines as HPK1 inhibitors and uses thereof | 百济神州有限公司 | 2022-02-25 | — | — | CN | disclosed |
| CN-112239473-A | Tricyclic compounds as HPK1 inhibitors | 百济神州(北京)生物科技有限公司 | 2021-01-19 | — | — | CN | disclosed |
| CN-112243439-A | Pyrrolo [2,3-B ] pyridines or pyrrolo [2,3-B ] pyrazines as HPK1 inhibitors and uses thereof | 百济神州有限公司 | 2021-01-19 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220267354-A1 | TRICYCLIC COMPOUNDS AS HPK1 INHIBITOR AND THE USE THEREOF | ULK1, SBK1, PHKG1 | ALDH1A1 4406/4885KMT2A 2585/4885OPRM1 4242/4885 |
| US-20220267333-A1 | PYRROLO[2,3-b]PYRAZINES AS HPK1 INHIBITOR AND THE USE THEREOF | PDXK, STK25, STK35 | ALDH1A1 3320/4885KMT2A 2605/4885OPRM1 4058/4885 |
| US-12454534-B2 | Pyrrolo[2,3-b]pyrazines as HPK1 inhibitor and the use thereof | PDXK, STK25, STK35 | ALDH1A1 3320/4885KMT2A 2605/4885OPRM1 4058/4885 |
| US-12459958-B2 | Tricyclic compounds as HPK1 inhibitor and the use thereof | ULK1, SBK1, PHKG1 | ALDH1A1 4406/4885KMT2A 2585/4885OPRM1 4242/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.